Sermorelin cost 2026, $99 to $216.18 a month

The continuing injection range

The compounded sermorelin injection page says prices were checked October 7, 2026. As of that date, it says CoreAge Rx publishes the lowest continuing medication-included price among the providers Telehealth Ledger tracks: $99 a month, continuing. It says 11 providers publish a comparable price, continuing prices run from $99 to $216.18 a month, and the median is $199. The page sorts featured rows so partner programs appear first, and it says the lowest-price sort uses the continuing price, with unpublished prices last.

The rows below are the priced injection offers on that page. Each check date is the date printed on the row. Shipping, lab work, and follow-up visits are charged separately by some companies, which the page states in its limits. Telehealth Ledger does not prescribe or dispense medication.

Why a $99 headline can be a different charge

The methodology page stores the introductory price, the continuing monthly price, the upfront charge, the prepaid effective monthly price, and the commitment length as separate fields. The sermorelin injection page uses those labels. CoreAge Rx's $99 is the continuing monthly price. bmiMD's $99 is the effective monthly price if someone pays $594 for 6 months, beside a $139 continuing price. TelePep's $99 is the effective monthly price if someone pays $1,188 for 12 months, beside a $159 continuing price. Comparing those three $99 figures as the same monthly bill treats a prepaid total as a month-to-month rate.

Luvo Health and Pallas Health are the rows that produce the $216.18 top of the range. Each lists $199 every 4 weeks, after a first period of $99.5 at Luvo Health and $139 at Pallas Health. The page prints $216.18 as the annualized monthly equivalent on a 365-day basis. It also says four-week charges are shown with their billing interval, and that the annualized average used for sorting is not a monthly bill. The $216.18 figure is that average. It is not a second invoice for $216.18 on top of the 4-week charge, and it is not the $199 every-4-weeks amount rewritten as a calendar-month price by this article.

The same page lists further providers without a comparable published price, including rows marked not published and quoted after intake. System Labs is marked not verified, with a note that current source variants disagree on the price and on monthly versus quarterly supply. Those rows are omitted from the table above because the page does not give them a ranked price.

Rank the continuing price when the page prints one. Read a prepaid effective rate together with the amount due up front. Read a 4-week price together with the billing interval.

Strut Health's injection price, and the separate oral page

On the injection page, Strut Health is marked as a partner program. The injection row is $119 a month, continuing, for a subcutaneous injection, checked October 7, 2026. The page says that offer is not available in Arkansas. Because partner rows are placed first, Strut Health can appear above CoreAge Rx even though $119 is higher than the $99 continuing price. The lowest-price sort on the page uses the continuing price.

Oral sermorelin is a different treatment page. Opened the same day, that page lists 4 priced providers and says continuing prices run from $99 to $179 a month, with a median of $114. Strut Health's oral row is $99 a month, continuing, for a 30-day sublingual lozenge supply, not available in Arkansas, checked October 7, 2026. MadeMed lists $99 a month, continuing, checked September 14, 2026. bmiMD lists $129 a month, continuing, or $89 a month if you pay $534 for 6 months, checked September 14, 2026. RxSpan MD lists $179 a month, continuing, checked September 14, 2026. The oral page says absorption by mouth differs from an injection, so the dose on the label is not directly comparable to the injectable version. The price module on this article is the injection catalog only.

What FDA says about compounded drugs in general

The injection rows are compounded sermorelin. FDA's page on the risks of compounded drugs says compounded drugs are not FDA-approved, and that the agency does not review their safety, effectiveness, or quality before they are marketed. It says compounded drugs can serve an important medical need for patients. It also says that if a compounded drug does not meet appropriate quality standards, such as if a drug is contaminated or contains too much active ingredient, it could cause serious injury or death, and that labels on compounded drugs may not include important information such as adequate directions for use.

The same page says FDA seeks to preserve access to lawfully marketed compounded drugs for patients who have a medical need for them, while protecting patients from compounded drugs that are not produced in accordance with applicable federal law. It says FDA continues to investigate reports of serious adverse events associated with contaminated or otherwise poor-quality compounded drugs, and that it continues to identify insanitary conditions at compounding facilities. The page does not name sermorelin, and it does not review the pharmacies behind the prices in the table. A price row does not establish that a compounded product meets those quality conditions.

This is a price comparison of published offers. It is not a safety clearance and it is not a recommendation to use sermorelin.

What the catalog can and cannot settle

A listed provider needs a commission-tracked visit link. The methodology page says the directory is not a census of every US telehealth company, and that an unpublished price is recorded as not published rather than estimated. State availability on the sermorelin page is a provider-level note, such as Strut Health's Arkansas limitation, and the page tells readers to confirm availability before intake when the row says it varies.

The page also says a clinician sets the dose after an intake questionnaire, and that the dose can change what someone pays. Nothing on the sources checked here records whether a particular reader will be prescribed sermorelin, what the out-the-door total will be after shipping or labs, or whether a plan covers the product. Those questions stay with the provider's current terms, the prescriber, and the payer.

• Is the offer the injection or the oral product?
• Is the figure a continuing monthly price, a first period, a prepaid effective rate, or a 4-week charge?
• If a prepaid rate is lower, what total is due up front, and for how many months?
• Does the published price include the medication?
• Which states does that provider's row say it does not serve, and what does the current checkout say?